Although corticosteroids have been the initial agent for the treatment of inflammatory myopathies (IM), immunosuppressive agents such as azathioprine, methotrexate, cyclophosphamide, or cyclosporine are commonly required to control the disease except mild cases. On the other hand, the efficacy of combination therapy of cyclosporine and methotrexate in severe rheumatoid arthritis has been proven without serious side effects. However, in treatment-resistant myositis, the experience of such a therapy is very limited, and has not been described in refractory polymyositis with anti-Jo-1 antibody. Here, we report a young female patient with recalcitrant polymyositis and anti-Jo-1 antibody who was successfully treated with the combination therapy of cyclosporine and methotrexate. At first, the myositis did not respond to several agents, such as corticosteroid, monthly pulse cyclophosphamide, azathioprine, or cyclosporine. Methotrexate was initially avoided as treatment regimen because of its potential pulmonary toxicity in the case with preexisting lung disease.
Adult ; Antibodies, Antinuclear/blood* ; Autoantigens/immunology ; Cyclosporine/administration & dosage ; Cyclosporine/therapeutic use* ; Drug Resistance ; Drug Therapy, Combination ; Female ; Histidine-tRNA Ligase/immunology ; Human ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/therapeutic use* ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use* ; Polymyositis/drug therapy* ; Polymyositis/immunology

This study was performed in order to characterize the types of the infiltrating cells, and the expression profiles of major histocompatibility complex (MHC) class I and membrane attack complex (MAC) in patients with inflammatory myopathies and dysferlinopathy. Immunohistochemical stains were performed using monoclonal antibodies against several inflammatory cell types, MHC class I, and MAC in muscles from inflammatory myopathies and dysferlinopathy. There was significant difference in the types of infiltrating cells between polymyositis (PM), dermatomyositis (DM), and dysferlinopathy, including significantly high CD4+/CD8+ T cell ratio and B/T cell ratio in DM. In dysferlinopathy, CD4+ T cells were the most abundant and the proportions of infiltrating cell types were similar to those of DM. MHC class I was expressed in muscle fibers of PM and DM regardless of the presence of inflammatory infiltrates. MAC was expressed in necrotic fibers and vessels of PM and DM. One patient with early stage DM had a MAC deposits on endomysial capillaries. In dysferlinopathy, MAC deposit was also observed on the sarcolemma of nonnecrotic fibers. The analysis of inflammatory cells, MHC class I expressions and MAC deposits may help to differentiate dysferlinopathy from idiopathic inflammatory myopathy.
Adult ; Aged ; *Dermatomyositis/immunology/pathology ; Female ; Genes, MHC Class I ; Humans ; Male ; *Membrane Proteins/genetics/immunology ; Middle Aged ; Muscle Fibers, Skeletal/cytology/immunology/pathology ; *Muscle Proteins/genetics/immunology ; *Muscular Dystrophies, Limb-Girdle/immunology/pathology ; *Myositis/immunology/pathology ; *Polymyositis/immunology/pathology ; T-Lymphocytes/cytology/immunology/pathology ; Young Adult